Guggenheim Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines (NASDAQ:ONC) had its price objective raised by investment analysts at Guggenheim from $420.00 to $430.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 30.50% from the company’s previous close.

A number of other equities analysts have also commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Wells Fargo & Company began coverage on BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 target price for the company. Leerink Partners lifted their target price on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Zacks Research cut BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 3rd. Finally, Truist Financial raised their price objective on BeOne Medicines from $413.00 to $416.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $395.77.

BeOne Medicines Stock Up 0.6%

Shares of NASDAQ ONC traded up $1.97 on Thursday, hitting $329.50. The company had a trading volume of 63,401 shares, compared to its average volume of 279,211. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. BeOne Medicines has a 12-month low of $253.95 and a 12-month high of $385.22. The firm has a market capitalization of $36.15 billion, a P/E ratio of 73.71 and a beta of 0.49. The business has a 50 day moving average of $294.53 and a two-hundred day moving average of $308.67.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.40 by $0.65. The business had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, equities research analysts forecast that BeOne Medicines will post 5.93 earnings per share for the current fiscal year.

Insider Transactions at BeOne Medicines

In other news, COO Xiaobin Wu sold 1,484 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $269.37, for a total transaction of $399,745.08. Following the completion of the transaction, the chief operating officer owned 40 shares in the company, valued at approximately $10,774.80. This trade represents a 97.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 145,861 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the completion of the transaction, the chief executive officer directly owned 8,122 shares in the company, valued at $2,484,925.90. This represents a 94.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 345,561 shares of company stock worth $105,625,947. 6.19% of the stock is owned by corporate insiders.

Institutional Trading of BeOne Medicines

Large investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers bought a new position in shares of BeOne Medicines in the second quarter valued at $455,000. Rhumbline Advisers acquired a new position in shares of BeOne Medicines in the 2nd quarter worth $275,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of BeOne Medicines during the second quarter valued at $505,000. Invesco Ltd. acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at $422,000. Finally, EverSource Wealth Advisors LLC purchased a new position in BeOne Medicines in the 2nd quarter worth about $68,000. 48.55% of the stock is currently owned by institutional investors.

Key Headlines Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Strong Q2 performance: BeOne reported earnings of $2.05 per share, exceeding the $1.40 analyst consensus, while revenue reached $1.71 billion versus expectations of $1.66 billion. Revenue reportedly increased 30% year over year, indicating continued momentum in the company’s oncology portfolio. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook raised: Management now expects full-year revenue of $6.6 billion to $6.8 billion, above the approximately $6.5 billion consensus estimate. The improved outlook suggests management sees sustained demand and operating strength. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analyst target increased: Citizens JMP raised its price target from $396 to $405 and maintained a “market outperform” rating, implying substantial potential upside from recent trading levels. Citizens JMP raises BeOne Medicines price target
• Neutral Sentiment: Insider sale disclosed: CFO Aaron Rosenberg sold 1,157 shares valued at approximately $362,000. The filing stated that the transaction was made to cover tax withholding connected with vested equity awards, making it a limited bearish signal. BeOne Medicines SEC insider filing
• Neutral Sentiment: Valuation remains elevated: Despite the favorable results, the stock trades at a high earnings multiple, leaving shares sensitive to any slowdown in growth or disappointing future guidance.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.